BRIEF published on 10/10/2024 at 07:05, 1 month 13 days ago Valneva presents its outlook at an investor day in New York Investors Growth Valneva Vaccines Lyme
PRESS RELEASE published on 10/10/2024 at 07:00, 1 month 13 days ago Valneva Hosts Investor Day in New York City Valneva SE is hosting an investor day in New York City to discuss key value drivers, including Lyme disease vaccine, commercial vaccines, and R&D pipeline. Hybrid event with webcast and Q&A sessions Investor Day Valneva SE Lyme Disease Vaccine R&D Pipeline Commercial Vaccines
BRIEF published on 10/04/2024 at 07:35, 1 month 19 days ago Valneva SE Announces Changes in Shares and Voting Rights Euronext Paris Voting Rights Shares Capital Increase Valneva SE
PRESS RELEASE published on 10/04/2024 at 07:30, 1 month 19 days ago Valneva SE - Declaration of shares and voting rights - September 30, 2024 Valneva declares changes in shares and voting rights, including a transfer into bearer form and a capital increase without preferential subscription rights Voting Rights Shares Capital Increase Transfer Valneva
BRIEF published on 10/03/2024 at 07:05, 1 month 20 days ago Valneva to Hold Investor Day in New York New York Investors Valneva Vaccines Chikungunya
PRESS RELEASE published on 10/03/2024 at 07:00, 1 month 20 days ago Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET Valneva SE to host Investor Day at Lotte New York Palace Hotel on Thursday, October 10, 2024, focusing on R&D pipeline and revenue-generating vaccines Investor Day Valneva SE Vaccine R&D Pipeline Lotte New York Palace Hotel
BRIEF published on 09/23/2024 at 15:51, 1 month 29 days ago Valneva Bolstered by Capital Raise Amid Strategic Focus on Vaccine Development BUY Rating Valneva SE Vaccine Development Equity Research Capital Raise
PRESS RELEASE published on 09/23/2024 at 15:46, 1 month 29 days ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Valneva SE (FR0004056851) with a BUY rating and a decreased price target to €7.70, reflecting the recent capital raise completed on 13 September 2024 BUY Rating Price Target Valneva SE Equity Research Capital Raise
BRIEF published on 09/23/2024 at 10:59, 1 month 29 days ago Bpifrance crosses the threshold of 10% of VALNEVA voting rights downwards Capital AMF Valneva Threshold Crossing Bpifrance
BRIEF published on 09/23/2024 at 10:58, 1 month 29 days ago Threshold Crossing at VALNEVA SE by Bpifrance Capital Valneva CDC Threshold Crossing Bpifrance
Published on 11/22/2024 at 23:55, 9 hours 15 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 40 minutes ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 10 hours 5 minutes ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 40 minutes ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 14 hours 55 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 15 hours 16 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 14 minutes ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 17 hours 10 minutes ago Proposed cancellation of admission to trading
Published on 11/21/2024 at 06:58, 2 days 2 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 13 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 15 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 15 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
